Though recent studies show this may not be true, the belief led to the development of agents to overcome GLP-1 deficiencies [19]
Several factors can diminish or prevent the expected weight loss response to GLP-1 receptor agonists, even when medications are administered correctly
Abbreviations CD: Crohns disease DPP-IV: Dipeptidyl peptidase IV DSS: Dextran sulfate sodium EEC: Enteroendocrine cells GI: Gastrointestinal tract GIP: Gastro-insulinotropic peptide GLP: Glucagon-like peptide GM-CSF: Granulocyte-macrophage colony-stimulating factor IBD: Inflammatory bowel diseases IFN-: Interferon IGF-1: Insulin-like growth factor 1 IL: Interleukin LPS: Lipopolysaccharide PC 1/3: Prohormone convertase 1/3 PEG: Polyethylene glycosyl SCFA: Short-chain fatty acids TNBS: 2,4,6-trinitrobenzenesulfonic acid TNF-: Tumor necrosis factor UC: Ulcerative colitis References Abrahami D, Douros A, Yin H, et al (2018) Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
GLP-1 medications support overall, systemic weight loss, while truSculpt targets the pockets of fat that even successful dieting can leave behind
With regard to safety concerns, the most prevalent adverse effects associated with GLP-1 RAs are gastrointestinal, such as bloating, dyspepsia, nausea, vomiting, diarrhea and constipation (107)
Does microdosing GLP-1 drugs still lead to weight loss